Undefined Antigen Based Vaccines

  • Check with publisher
  • Published date: January 28, 2019
    • Shirley, New York, United States

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best development services for undefined antigen-based vaccines. We guarantee the finest results for our customers all over the world.

A rationale for using undefined antigen vaccines to treat patients with cancer is that for the most common types of malignancy, e.g. carcinomas of epithelial origin, tumor antigens have not been well-characterized. Furthermore, in contrast to defined antigen vaccines, vaccines using intact tumor cells, or preparations derived from whole tumor cells, contain not only shared tumor antigens, but also many TSA, to which the host may not have developed tolerance.

Result 0 votes
Jerry Carter
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • 5th Annual Advances in Immuno-Oncology Congress

    5th Annual Advances in Immuno-Oncology Congress

    Life Sciences London (London) November 12, 2019 Check with publisher

    Over 350 attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic and healthcare institutions developing immuno-oncology therapies and tools. Over 60 presentations, case studies and p...

  • 7th Annual Peptides & Oligonucleotides Congress

    7th Annual Peptides & Oligonucleotides Congress

    Life Sciences London (United Kingdom) November 6, 2019 Check with publisher

    Over 150 attendees working in peptides and oligonucleotides, representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions. Over 40 case studies, presentations and panel discussions foc...

  • Recombinant Huaiyangshan Virus Nucleocapsid Protein (aa 1-252) [His]

    Recombinant Huaiyangshan Virus Nucleocapsid Protein (aa 1-252) [His]

    Life Sciences Shirley (New York) October 28, 2019 Check with publisher

    Huaiyangshan virus (HYSV) is a novel tick-borne bunyavirus. It causes haemorrhagic fever-like disease and has recently been reported in China. https://www.creative-biolabs.com/vaccine/recombinant-huaiyangshan-virus-nucleocapsid-protein-aa-1-252-his-6...